These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 30241606)
1. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Coscia F; Lengyel E; Duraiswamy J; Ashcroft B; Bassani-Sternberg M; Wierer M; Johnson A; Wroblewski K; Montag A; Yamada SD; López-Méndez B; Nilsson J; Mund A; Mann M; Curtis M Cell; 2018 Sep; 175(1):159-170.e16. PubMed ID: 30241606 [TBL] [Abstract][Full Text] [Related]
2. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711 [TBL] [Abstract][Full Text] [Related]
3. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578 [TBL] [Abstract][Full Text] [Related]
4. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581 [TBL] [Abstract][Full Text] [Related]
5. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486 [TBL] [Abstract][Full Text] [Related]
6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
7. Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. Bateman NW; Jaworski E; Ao W; Wang G; Litzi T; Dubil E; Marcus C; Conrads KA; Teng PN; Hood BL; Phippen NT; Vasicek LA; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Darcy KM; Conrads TP J Proteome Res; 2015 Apr; 14(4):1900-10. PubMed ID: 25748058 [TBL] [Abstract][Full Text] [Related]
8. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210 [TBL] [Abstract][Full Text] [Related]
9. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways. Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068 [TBL] [Abstract][Full Text] [Related]
10. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060 [TBL] [Abstract][Full Text] [Related]
11. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814 [TBL] [Abstract][Full Text] [Related]
12. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum]. Wu WJ; Wang Q; Zhang W; Li L Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871 [TBL] [Abstract][Full Text] [Related]
13. A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma. Sun CY; Su TF; Li N; Zhou B; Guo ES; Yang ZY; Liao J; Ding D; Xu Q; Lu H; Meng L; Wang SX; Zhou JF; Xing H; Weng DH; Ma D; Chen G Oncotarget; 2016 Jan; 7(3):3245-54. PubMed ID: 26675546 [TBL] [Abstract][Full Text] [Related]
14. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315 [TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer. Mariya T; Hirohashi Y; Torigoe T; Asano T; Kuroda T; Yasuda K; Mizuuchi M; Sonoda T; Saito T; Sato N Cancer Immunol Res; 2014 Dec; 2(12):1220-9. PubMed ID: 25324403 [TBL] [Abstract][Full Text] [Related]
16. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis. Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541 [TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557 [TBL] [Abstract][Full Text] [Related]
18. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. Chen YT; Hsu M; Lee P; Shin SJ; Mhawech-Fauceglia P; Odunsi K; Altorki NK; Song CJ; Jin BQ; Simpson AJ; Old LJ Int J Cancer; 2009 Jun; 124(12):2893-8. PubMed ID: 19296537 [TBL] [Abstract][Full Text] [Related]